Current Advances in Lipid-Based Drug Delivery Systems as Nanocarriers for the Management of Female Genital Tuberculosis.

Female genital tuberculosis (FGTB) arises from infection and can rarely be caused by or atypical mycobacteria. FGTB usually arises from tuberculosis (TB) that affects the lungs or other organs. The infection can enter the vaginal tract directly from abdominal TB or by hematogenous or lymphatic pathways.

Unlocking the Future: New Biologic Therapies for Rheumatoid Arthritis.

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that leads to joint destruction and functional disability. Traditional treatments, including disease-modifying antirheumatic drugs (DMARDs), often fail, leaving many patients without remission. The advent of biologic therapies that target specific immune system components (e.

Theranostic Applications of Scaffolds in Current Biomedical Research.

Theranostics, a remarkable combination of diagnostics and therapeutics, has given rise to tissue/organ-format theranostic scaffolds that integrate targeted therapy and real-time disease monitoring. The scaffold is a 3D structuring template for cell or tissue attachment and growth. These scaffolds offer unprecedented opportunities for personalized medicine and hold great potential for revolutionizing healthcare.

Digital Ischemia and Gangrene: An Unusual Presentation of Chronic Myeloid Leukemia.

Digital ischemia with gangrene is a rare manifestation of chronic myeloid leukemia (CML). We report a rare CML case with severe thrombocytosis presenting clinically as digital ischemia and gangrene, the sole primary symptom. A 40-year-old patient presented with pain and discoloration of the tips of the ring and little fingers of the right hand for 20 days, which later progressed to dry gangrene with a line of demarcation and pre-gangrenous changes in the index and middle fingers.

Recent Advances in the Development and Utilization of Nanoparticles for the Management of Malignant Solid Tumors.

The purpose of nanotechnology-based drug delivery systems or novel drug delivery systems is to improve the effectiveness of therapy, and their promising properties have led to their increasing significance in the management of cancer. The researchers have primarily focused on designing novel nanocarriers, like nanoparticles (NPs), that can effectively deliver drugs to target cells and respond specifically to conditions particular to cancer. Whether passive or active targeting, these nanocarriers can deliver therapeutic cargoes to the tumor site to release the drug from the drug delivery systems.